Home / Business and Economy / Zim Labs Capsules: Pain Relief Meets Gastric Protection
Zim Labs Capsules: Pain Relief Meets Gastric Protection
3 Dec, 2025
Summary
- Zim Labs received CDSCO approval for a new FDC drug.
- The drug combines Naproxen Delayed Release and Esomeprazole.
- It is indicated for arthritis and reducing ulcer risk in adults.
Zim Laboratories announced a significant milestone with the CDSCO's approval for its novel fixed-dose combination (FDC) of Naproxen Delayed Release and Esomeprazole capsules. This advanced formulation, developed using the company's proprietary drug delivery technologies, integrates delayed-release naproxen minitablets with esomeprazole pellets into a single hard gelatin capsule. This innovation represents a differentiated and patient-friendly delivery system.
The newly approved FDC is specifically indicated for adults seeking symptomatic relief from conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Crucially, it also aims to reduce the risk of NSAID-associated gastric and duodenal ulcers. The approval reinforces Zim Laboratories' strategic focus on the pain management and gastro-protective market segments.
Zim Laboratories anticipates launching this product in India by FY 2026-27, having already established a commercial supply agreement with an Indian pharmaceutical firm. This development aligns with the company's strategy of creating innovative, differentiated generics through advanced formulation technologies, further solidifying its position in the pharmaceutical landscape.
